ESR1 and breast cancer: Therefore, the 8th edition of the American Joint Committee on Cancer (AJCC) Staging established combined multiple molecular markers in addition to the traditional clinical staging, estrogen receptors (ER), progesterone receptors (PR), and Herceptin (HER-2) biological markers for the evaluation of BC (Giuliano et al. 2018).